Heart failure with preserved ejection fraction (HFpEF) is a common and challenging form of heart failure, especially prevalent among people with obesity and type 2 diabetes1 . Patients with HFpEF often face frequent hospitalizations and a high risk of death, with limited effective treatment options available1 . Recent studies indicate that tirzepatide, a dual GIP/GLP-1 receptor agonist, may significantly reduce the risk of heart failure hospitalization and mortality in this population2 .
How Zepbound Works for Heart Failure and Obesity
Tirzepatide, marketed as Zepbound and Mounjaro, is a novel medication that targets two key receptors involved in metabolism: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors3 . These receptors are expressed not only in the pancreas but also in heart and vascular tissues, allowing tirzepatide to influence cardiovascular function directly3 4. By activating these receptors, tirzepatide improves insulin secretion, reduces appetite, and promotes weight loss, which are critical factors in managing obesity and type 2 diabetes3 4.
Obesity is a major risk factor for HFpEF, contributing to left ventricular stiffness and impaired heart filling5 6. Nearly 60% of U.S. patients with HFpEF are obese, making weight management a crucial therapeutic target5 6. Tirzepatide’s ability to induce substantial weight loss helps reduce the burden of obesity on the heart, potentially improving heart function and symptoms7 8.
The SUMMIT trial, an international, double-blind, placebo-controlled study, enrolled 731 patients with HFpEF and obesity to evaluate tirzepatide’s effects over 52 weeks7 . Participants had a body mass index (BMI) of at least 30 kg/m² and an ejection fraction of 50% or greater, indicating preserved pumping function but impaired relaxation of the heart muscle7 9. The trial demonstrated that tirzepatide led to significant improvements in heart failure outcomes, including reductions in cardiovascular death and worsening heart failure events7 9.
Key mechanisms by which tirzepatide benefits heart failure and obesity include:
- Dual activation of GIP and GLP-1 receptors improves insulin sensitivity and glucose metabolism3 4.
- Weight loss reduces cardiac workload and systemic inflammation associated with obesity7 8.
- Direct cardiovascular effects through receptor expression in heart and blood vessels enhance heart function3 4.
- Improvement in kidney function, which often coexists with HFpEF and obesity, further supports cardiovascular health8 .
These combined effects address the complex interplay between obesity, diabetes, kidney disease, and heart failure, offering a comprehensive therapeutic approach8 .
“The interplay of these three conditions identifies a patient population as exceptionally high risk, which means it's a patient population that is exceptionally in need of treatments that work. This drug improves kidney function, obesity and HFpEF outcomes, thus improving all three elements that interact to create this syndrome.”
— Milton Packer, Baylor University Medical Center8
Tirzepatide's Heart Health Benefits
Heart failure with preserved ejection fraction accounts for about half of all heart failure cases, characterized by stiffening of the left ventricle that impairs its ability to fill properly during diastole5 10. Patients with HFpEF often experience fatigue, shortness of breath, and frequent hospitalizations due to worsening heart failure5 . Until recently, no therapies had conclusively reduced mortality or hospitalization in this population7 .
The SUMMIT trial revealed that tirzepatide significantly lowered the composite risk of cardiovascular death, urgent heart failure visits, and hospitalizations by 38% compared to placebo7 . Worsening heart failure events were reduced by 46%, demonstrating a robust protective effect2 . Patients treated with tirzepatide also showed meaningful improvements in functional capacity and quality of life, as measured by the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), which increased by 6.9 points more than placebo at 52 weeks7 92.
Additional benefits observed in the trial included:
- A mean weight loss of approximately 15.7% in the tirzepatide group versus 2.2% with placebo, easing cardiac strain7 .
- Improved six-minute walk distance by an average of 18.3 meters, reflecting better exercise tolerance2 .
- Reduction in inflammatory biomarkers linked to heart failure progression11 .
- Decreased medication burden for heart failure, indicating better disease control12 .
Real-world data analyses support these findings. A large study of over 90,000 patients with HFpEF, obesity, and type 2 diabetes showed that initiation of tirzepatide or semaglutide was associated with more than a 40% reduction in the risk of hospitalization for heart failure or all-cause mortality compared to sitagliptin, a diabetes drug without heart failure benefits1 13. Both drugs had similar effectiveness and acceptable safety profiles1 1314.
A propensity-matched analysis of patients with heart failure without diabetes also demonstrated that tirzepatide use was linked to significantly lower risks of acute heart failure, major adverse cardiovascular events (MACE), stroke, chronic kidney disease progression, and coronary artery disease compared to untreated patients15 . These results highlight tirzepatide’s broad cardiovascular protective effects beyond glycemic control.
“Despite the widespread morbidity and mortality burden of HFpEF, current treatment options are limited. Both semaglutide and tirzepatide are well-known for their effects on weight loss and blood sugar control, but our study suggests they may also offer substantial benefits to patients with obesity and Type 2 diabetes by reducing adverse heart failure outcomes.”
— Nils Krüger, Brigham and Women's Hospital, Harvard Medical School1
- 38% reduction in cardiovascular death or worsening heart failure events7 2
- 46% reduction in worsening heart failure events alone2
- Significant weight loss (~15.7%) improving cardiac workload7
- Improved quality of life and functional capacity (KCCQ-CSS, 6-minute walk test) 92
- Reduced inflammatory markers and medication burden11 12
- Over 40% lower risk of hospitalization or death in real-world HFpEF patients with obesity and diabetes1 13
Future Heart Failure Treatment With Zepbound
Tirzepatide’s dual agonism of GLP-1 and GIP receptors offers a promising new therapeutic avenue for heart failure, particularly HFpEF associated with obesity and metabolic disease3 16. GLP-1 receptor agonists, such as semaglutide, have already demonstrated cardiovascular benefits including reductions in myocardial infarction, stroke, and heart failure symptoms17 16. Tirzepatide may provide superior efficacy due to its combined receptor targeting, leading to greater weight loss, glycemic control, and cardiovascular risk reduction3 18.
Ongoing and future clinical trials aim to further clarify tirzepatide’s role in heart failure management and cardiovascular risk reduction16 . The drug’s benefits extend beyond heart failure to related comorbidities such as chronic kidney disease and sleep apnea, which often coexist in this high-risk population11 8.
Key points supporting tirzepatide’s future in heart failure treatment include:
- Direct cardiovascular effects through receptor expression in heart and vessels3 4.
- Reduction in systolic blood pressure and LDL cholesterol, important risk factors for cardiovascular disease19 6.
- Improvement in kidney function, which is closely linked to heart failure outcomes8 .
- Superior cardiovascular outcomes compared to GLP-1 receptor agonists alone, such as semaglutide, in some patient populations20 .
- Favorable safety and tolerability profiles supporting long-term use21 14.
Despite these promising findings, tirzepatide’s use for heart failure remains investigational pending full peer-reviewed publication of trial data and regulatory approval for this indication7 11. Clinicians should carefully weigh benefits and risks and consult with patients before initiating therapy21 .
“Most patients with obesity who have HFpEF and chronic kidney disease are not getting any effective treatment. We were very pleased to see the improvement in kidney function, which paralleled the favorable effects on the heart and on obesity.”
— Milton Packer, Baylor University Medical Center8
- Tirzepatide dosing in trials ranged from 5 to 15 mg weekly, titrated based on tolerability11 .
- Monitoring for gastrointestinal side effects and other adverse events is important22 23.
- Integration with guideline-directed medical therapy for heart failure is essential, as current use of heart failure drugs remains suboptimal24 .
- Further research is needed to establish long-term cardiovascular outcomes and safety in diverse populations7 16.
